A better comprehension of one’s cancer can provide improved treatment outcomes. It’s easier to fight something that one understands. That’s why a recent article published in Medical Xpress is so exciting; scientists have identified protein markers that can indicate the severity of chronic lymphocytic leukemia (CLL). The research was originally published in the Journal of Leukocyte Biology, and it can aid doctors in the diagnostic and treatment processes.
New Protein Markers for CLL
Because CLL is the most common form of leukemia in the Western world, new information and better understandings can make a big impact on many patients. In this case, doctors have a better idea of their patients’ prognoses with these protein markers.
Research could be improved as well. Medical professionals working on treatments for CLL may get a better idea of potential therapeutic targets.
Speaking about this recent discovery, the lead author of the study, Cristina Bagacean, Ph.D., said,
“This approach could identify putative therapeutic targets in order to prevent CLL progression.”
About CLL
Chronic lymphocytic leukemia is a rare cancer of the bone marrow and blood. Affected individuals do not have properly functioning bone marrow, as it produces abnormal white blood cells – specifically lymphocytes – which then crowd out healthy cells. Doctors are unsure as to why this happens; all they know is that a genetic mutation occurs for some reason within the blood-producing cells of the bone marrow. Regardless of the cause, CLL causes symptoms like night sweats, fever, fatigue, weight loss, enlarged spleen, pain in the abdomen, frequent infections, and enlarged but painless lymph nodes. After diagnosing this cancer, treatment options consist of chemotherapy, targeted therapy, and a bone marrow transplant.